Kyowa Kirin Co., Ltd.
Quick facts
| Founded | 1949 |
|---|
Marketed products
- KHK4827-Active
- KRN23 · Endocrinology / Rare Metabolic Disorders
KRN23 is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23), restoring phosphate reabsorption and vitamin D metabolism in patients with X-linked hypophosphatemia. - Mitozytrex · Oncology
Phase 3 pipeline
- EN3267 · Immunology
EN3267 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 axis to reduce inflammatory cell recruitment and activation. - KHK4827 · Cardiovascular
KHK4827 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway. - KHK7580 · Cardiovascular
KHK7580 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway. - KHK7791 · Cardiovascular
KHK7791 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key coagulation cascade enzyme, thereby reducing thrombotic risk. - KK8398 · Immunology
KK8398 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 signaling pathway to reduce inflammatory cell recruitment and activation. - KW-2246 · Oncology
KW-2246 is a humanized monoclonal antibody that binds to and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity. - KW-2246 (fentanyl citrate) · Pain Management
KW-2246 is a fentanyl citrate formulation that binds to opioid receptors in the central nervous system to produce analgesia and pain relief. - KW-6500 · Endocrinology
KW-6500 is a long-acting growth hormone secretagogue that stimulates growth hormone release by activating ghrelin receptors. - OPC-262 · Immunology
OPC-262 is a selective and potent inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1). - Plasma-derived antithrombin · Cardiovascular
Plasma-derived antithrombin is a protein that inhibits the coagulation cascade by binding to and neutralizing thrombin and other coagulation factors. - saxaglipitin · Other
Phase 2 pipeline
- KHK4083 · Diabetes
KHK4083 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). - KHK4563
- KHK4577
- KHK4951
- KHK6188
- KHK7580 high dose
- KHK7580 low dose
- KHK7580 middle dose
- KRN321
- ME-401
Phase 1 pipeline
- KHK2375
- KHK6640
- KK2260
- KK2269
- KK2845_1
- KK2845_2
- KK2845_3
- KK2845_4
- KK2845_5
- KK2845_6
- KK3910
- KK4277
- KK8123
- KRN951
- KW-6356 High Dose
- KW-6356 Low Dose
- KW-6356 Middle Dose
- KW-6356 X Dose
- KW-6356 Y Dose
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Kyowa Kirin Co., Ltd.
What are Kyowa Kirin Co., Ltd.'s marketed drugs?
Top marketed products include KHK4827-Active, KRN23, Mitozytrex.
What is Kyowa Kirin Co., Ltd.'s pipeline?
Kyowa Kirin Co., Ltd. has 11 drugs in Phase 3, 10 in Phase 2, 19 in Phase 1. Late-stage candidates include EN3267, KHK4827, KHK7580, KHK7791.
When was Kyowa Kirin Co., Ltd. founded?
Kyowa Kirin Co., Ltd. was founded in 1949.
How many employees does Kyowa Kirin Co., Ltd. have?
Kyowa Kirin Co., Ltd. has approximately 7,152 employees.
Related
- KHK4827-Active
- KRN23 · Endocrinology / Rare Metabolic Disorders
- Mitozytrex · Oncology
- Sector hub: All tracked pharma companies